| 项目编号 | PRJCA048991 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 项目标题 | scMulti-omics Reveals that Bortezomib Pre-treatment Enhances the Anti-tumor Efficacy of CD19 CAR T Cells | ||||||||||||||||
| 涉及领域 | Medical | ||||||||||||||||
| 数据类型 |
Epigenomics
Transcriptome or Gene expression Raw sequence reads Single cell sequencing |
||||||||||||||||
| 物种名称 | |||||||||||||||||
| 描述信息 | Our previous data showed that CAR T cells with high proteasome activity exhibit reduced therapeutic efficacy due to their tendency to undergo terminal differentiation. We hypothesized that incorporating proteasome inhibitors during human CAR T cell production could reduce their propensity for exhaustion and enhance their therapeutic efficacy. Pre-treatment of CAR T cells during manufacturing with a low dose of bortezomib, an FDA, approved proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma, significantly improved their anti-tumor efficacy. To investigate how short-term bortezomib treatment prolongs the survival of leukemia-bearing mice, we performed single-cell multi-omics (scMulti-omics) analysis. The results revealed that bortezomib pre-treatment increased memory-like cell clusters and reduced the chromatin accessibility of HAVCR2 and PRDM1, genes associated with T cell exhaustion. | ||||||||||||||||
| 样品范围 | Single cell | ||||||||||||||||
| 发布日期 | 2026-01-25 | ||||||||||||||||
| 项目资金来源 |
|
||||||||||||||||
| 提交者 | Yingxi Xu (xuyingxi@ihcams.ac.cn) | ||||||||||||||||
| 提交单位 | Peking Union Medical College | ||||||||||||||||
| 提交日期 | 2025-09-05 |
| 资源名称 | 描述 |
|---|---|
| BioSample (4) | - |
| SAMC6561316 | S2D_Bort |
| SAMC6561315 | S2C_DMSO |
| SAMC6561314 | S2B_Bort |
| SAMC6561313 | S2A_DMSO |